Heart failure & cardiomyopathiesSecondary analysis
Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Among Women and Men
- Secondary analysis of the MOMENTUM 3 study
- multicentre
Authors' conclusion
There were no differences in the primary composite endpoint or overall survival in women compared with men at 2 years of support.
Study context
- Population
- HeartMate3 LVAD recipients with advanced HF20.4% women
- Participants
- 2,200 recipients
- Comparison
- Women vs men with HeartMate3 (HM3) LVAD
- Womenn = 448
Primary result
As reported in the abstract
2 years
Adjusted hazard ratio
0.96
95% CI 0.75–1.24
P = 0.66
By group
Women vs Men
aHR 0.96 (95% CI 0.75–1.24); P = 0.66
Further findings
| Outcome | Women | Men | aHR (95% CI) | P value | |
|---|---|---|---|---|---|
| Overall survival · 2 years | 82.4% | 80.2% | 1.06 (0.81–1.40) | P = 0.66 | |
| 0.512Adjusted hazard ratio (log scale) |
6-minute walk distance and quality of life
- Similar gains in both groups
Safety
| Outcome | aIRR (95% CI) | P value |
|---|---|---|
| Stroke, major bleeding, infection — Women vs Men · stroke | 1.52 (1.09–2.11) | P = 0.012 |
| Stroke, major bleeding, infection — Women vs Men · major bleeding | 1.28 (1.15–1.42) | P < 0.0001 |
| Stroke, major bleeding, infection — Women vs Men · infection | 1.14 (1.03–1.55) | P = 0.01 |
Stroke, major bleeding, infection
- Differences not seen among older (>65 years) patients
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device Among Women and Men. JACC Heart Fail. Published 11 October 2023. doi:10.1016/j.jchf.2023.08.020
Summarised from the published abstract; every number is checked against it